Quest Diagnostics (MEX:DGX) Growth Rank : 0 (As of Dec. 12, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Quest Diagnostics Growth Rank?

Quest Diagnostics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Quest Diagnostics Growth Rank Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Quest Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (MEX:DGX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

DGX:USA 0KSX:UK QDI:Germany QDI:Germany Q1UE34:Brazil

Address

500 Plaza Drive, Secaucus, NJ, USA, 07094

Website

https://www.questdiagnostics.com

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.